Результаты поиска

A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.

ObjectiveThis study aims to analyze the impact of the eOncosalud app on the management and follow-up of adverse effects (AE) in patients receiving oral antineoplastic agents.Material and methodsWe performed an observational, prospective study of cancer outpatients treated with oral antineoplastic agents (OAA), monitored by the eOncosalud app between August 2017 and October 2021. Safety variables were collected from eOncosalud: the number of AE; severity of the AE according to CTCAE, version 4.03; timelapse from app installation to first recorded AE; automatic recommendations issued; and the pa

Совпадение в полном тексте источника
… Tumor | Number | Percentage Breast Palbociclib Ribociclib Abemaciclib Everolimus Capecitabine | 42 19 10 5 7 1 | 22.6% Lung Osimertinib Afatinib Gefitinib Erlotinib Crizotinib Alectinib Nintedanib | 21 6 3 3 3 2 2 2 | 11.3% Prostate Enzalutamide Abiraterone | 18 10 8 | 9.7% Renal Pazopanib Tivozanib Sunitinib … Ovarian Olaparib Niraparib | 16 10 6 | 8.6% Chronic lymphoid leukemia Ibutinib Venetoclax | 10 9 1 | 5.4% Gastrointestinal stromal tumor Imatinib Regorafenib | 9 7 2 | 4.8% Hepatocarcinoma Sorafenib Regorafenib | 9 6 3 | 4.8% Multiple myeloma Lenalidomide Thalidomide | 8 7 1 | 4.30% Sarcoma Pazopanib Sunitinib …

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.

PURPOSE: This study evaluated the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer who received denosumab or zoledronic acid (ZA) for treating bone metastasis. METHODS: The medical records of patients were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. The primary endpoint was a comparison of the risk of developing MRONJ between the denosumab and ZA groups. Propensity score matching was used to control for baseline differences between patient characteristics and compare outcomes for both groups. RESULT

Совпадение в полном тексте источника
… bone-modifying agent; ZA, zoledronic acid Table 1 Patient characteristics before and after propensity score matching For continuous values, data are presented as the median (interquartile range [ IQR ]) a Includes axitinib, bevacizumab, everolimus, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib … jaw in patients who received denosumab or zoledronic acid for bone metastasis N/A indicates that the covariate was not included in the model because it was not significant in univariate analyses a Includes axitinib, bevacizumab, everolimus, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib …

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

BackgroundZalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy.MethodsUsing in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified

Совпадение в полном тексте источника
… Imatinib and sunitinib also inhibit PDGFRα and c-Kit and other RTKs, such as VEGFR1 and FLT3, whereas sorafenib appears to be more specific for PDGFRβ but also inhibits c-Kit, FLT3, and VEGFR2. Nilotinib inhibits PDGFRα and -β and c-Kit. … Mattingly RR Milstein ML Mirkin BL Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells Cell Signal 2001 13 7 499 505 10.1016/S0898-6568(01)00173-5 11516625 Takeuchi A Eto M Shiota M Tatsugami K Yokomizo A Kuroiwa K Itsumi M Naito S Sunitinib …

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.

The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs currently. In this review, the characteristics and interaction of bone metastases and their immune microenvironment were systematically discussed, and the relevant research progress of the immunological mechanism of tumor bone metastasis was reviewed. On this basis, we expounded the clinical application of immune checkpoint inhibitors for bone metastasis of common tumors, includi

Совпадение в полном тексте источника
… Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine . 2019;380(12):1116–1127. doi: 10.1056/NEJMoa1816714. 134. Motzer R. J., Penkov K., Haanen J., et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. … Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open- label, phase 3, randomised controlled trial. Lancet . 2019;393(10189):2404–2415. doi: 10.1016/S0140-6736(19)30723-8. 137. …

Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.

BackgroundImmune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt.MethodsIn this systematic review, phase 3 randomized controlled trials investigating pembrolizumab in advanced cancers and providing subgroup analyses of Asian and non-Asian participants were included. The primary and secondary effect measures were the mean differences (MDs) in the natural logarithms of the hazard ratios (HRs) for overall survival (OS) and progression-free survival

Совпадение в полном тексте источника
… Pembrolizumab plus axitinib versus sunitinib monotherapy as first‐line treatment of advanced renal cell carcinoma (KEYNOTE‐426): extended follow‐up from a randomised, open‐label, phase 3 trial . … Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the east Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial . …

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.

BACKGROUND: Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network ("Rete Oncologica Piemonte e Valle d'Aosta"), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. MATERIAL AND METHODS: MRONJ cases were collected retrospectively from January 2009 to

Совпадение в полном тексте источника
… Eight cases of MRONJ (1.7%) were detected on patients under antiangiogenics without history of antiresorptive treatment (4 bevacizumab, 4 sunitinib). … Out of 52 patients undergoing antiresorptive drugs, either alone or as a sequence, with biological agents, 12 received thalidomide, 11 lenalidomide, 11 bevacizumab, 9 everolimus, and 9 sunitinib. …

CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour.

Gastrointestinal stromal tumours (GISTs) are the most common human sarcomas and are typically located in the stomach or small intestine. Although circular RNAs (circRNAs) reportedly play vital roles in tumour oncogenesis and progression, the molecular basis of the aggressive tumour biology of these circRNAs in GISTs remains unclear. In this study, we applied SBC ceRNA microarrays to screen for tumour-specific circRNA profiles in GISTs and identified that a total of 5,770 circRNAs and 1,815 mRNAs were differentially expressed in GISTs. Three significantly differential circRNAs (circ_0069765, ci

Совпадение в полном тексте источника
… Sunitinib and regorafenib are two additional multikinase inhibitors approved as second- and third-line therapies, respectively, and are available for the treatment of imatinib-resistance GIST ( Demetri et al., 2006 ; Demetri et al., 2013 ). … Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338. 10.1016/S0140-6736(06)69446-4 Demetri G. D., Reichardt P., Kang Y. K., Blay J. …

Pyoderma gangrenosum у пациента с множественным склерозом при лечении в ходе родовспоможения: отчет по делу.

Пёдерма Гангреносум (PG) часто рассматривается в качестве иммунной болезни. До 50% случаев ПГ - редкое, неинфекционное воспалительное заболевание кожи, характеризующееся болезненными некротическими язвами, - связано с такими основополагающими системными заболеваниями, как ремуматуидный артрит (RA) и инфламматический болезень Боулинга (IDB), а также с моноклональной антителной терапией. Мы описали 38-летнюю пациентку с множественным склерозом (MS), которая три года лечилась от Натализумаба. Myalgia, лихорадка и эритимные доски, сопровождаемые болезненными повреждениями в обеих верхних конечност

Совпадение в полном тексте источника
… In several literatures there are reported cases of PG among individuals who were receiving chemotherapy agents including Imatinib [ 17 , 18 ], Sunitinib [ 19 ], Lenalidomide [ 20 , 21 ], Lenvatinib [ 22 , 23 ], cabozantinib [ 24 ]. …

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

PURPOSE: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, or ZA-to-denosumab for the treatment of bone metastases. METHODS: The medical charts of patients with cancer who received denosumab or ZA for bone metastases were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. Primary endpoint was the evaluatio

Совпадение в полном тексте источника
… –17) 8 (3–19) For continuous values, data are presented as the median [interquartile range (IQR)] BMA bone-modifying agent, MRONJ medication-related osteonecrosis of the jaw, ZA zoledronic acid a Includes axitinib, bevacizumab, everolimus, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib … characteristics For continuous values, data are presented as the median [interquartile range (IQR)] BMA bone-modifying agent, MRONJ medication-related osteonecrosis of the jaw, ZA zoledronic acid a Includes axitinib, bevacizumab, everolimus, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib …

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.

The neoplastic "stromal" cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic "stromal" cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which ide

Совпадение в полном тексте источника
… Inhibition of PDGFRβ signaling with sunitinib affects the cell viability of the neoplastic cells in vitro and caused the complete depletion of giant cells and neoplastic cells in one patient [ 30 ]. … New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling Cancers 2021 13 3543 10.3390/cancers13143543 34298757 PMC8305892 31. Bradley E.W. Carpio L.R. van Wijnen A.J. …

Longitudinal survival trends of patients with cancer with surgically managed appendicular metastatic bone disease: systematic review.

BackgroundAdvances in systemic cancer therapies have improved survival for patients with metastatic carcinoma; however, it is unknown whether these advances have translated to improved survival for patients with appendicular metastatic bone disease (A-MBD) after orthopedic interventions. We conducted a study to evaluate the trend in overall survival for patients who underwent orthopedic surgery for A-MBD between 1968 and 2018.MethodsA systematic search of Embase and Medline to identify studies published since 1968 evaluating patients treated with orthopedic surgery for A-MBD was conducted for

Совпадение в полном тексте источника
… Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018;94:115–25. 15. … Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011;22:794–800. 101. Tevaarwerk AJ, Gray RJ, Schneider BP, et al. …

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis are adverse hypersensitivity reactions that affect the skin and mucous membranes. They are characterised by erythematous macules and hemorrhagic erosions of the mucous membranes. Epidermal detachments of varying degrees of severity also occur in these conditions. Various aetiologies are associated with these conditions, with adverse drug reaction being the most common. Though the worldwide incidence of these conditions is recorded as low, diverse types of medication are being observed to lead to these conditions. This review compiles in

Совпадение в полном тексте источника
… Sunitinib: A patient was treated with Sunitib for renal cell carcinoma with metastasis to the lung. On day 14 of treatment, the patient presented with SJS [ 54 ]. Xanthine oxidase inhibitor Allopurinol: Commonly used in the treatment of chronic gout. … ://doi.org/10.5021/ad.2011.23.S3.S343 PMid:22346274 PMCid: PMC3276793 22346274 10.5021/ad.2011.23.S3.S343 PMC3276793 53 Jha P Himanshu D Jain N Singh AK Imatinib-induced Stevens-Johnsons syndrome BMJ case reports 2013 2013 bcr2012007926 10.1136/bcr-2012-007926 PMC3604560 23349042 54 Lee J Case of sunitinib-induced …

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between cancer cells and the TME is crucial in understanding cancer progression and therapeutic challenges. A critical process induced by TME signaling is the epithelial-mesenchymal transition (EMT), wherein epithelial cells acquire mesenchymal traits, which enhance their motility and inva

Chimeric antigen receptor-based cell therapy for treating urological tumors.

Urological tumors represent a significant global health challenge, with conventional therapies often proving insufficient to control disease progression. Recent breakthroughs in cellular immunotherapy, particularly in chimeric antigen receptor (CAR)-T cell, CAR-natural killer cell, and CAR-macrophage therapies, have demonstrated remarkable potential for treating these malignancies. Ongoing research is actively refining CAR-based strategies to enhance their precision in targeting tumor-associated antigens. This review comprehensively summarizes the applications of CAR cell therapy in the follow

Совпадение в полном тексте источника
… | Preclinical | • Secretes anti-PD-L1 antibodies in NSG mice • Synergistic effect with sunitinib in RCC cells | | AXL/ROR2 | Phase I/II | • Expressed in RCC and contributes to tumor growth and invasiveness • No dose-limiting toxicity in r/r metastatic RCC ( NCT03393936 ) | | VEGFR2 | Phase I/II … Mori et al. [ 23 ] have reported that c-Met–specific CAR-T cells infiltrated tumors in orthotopic models (6-week-old male and female NOD mice), with improved efficacy when combined with sunitinib (a multitarget inhibitor of VEGFR1, VEGFR2, VEGFR3, platelet-derived growth factor receptor β, and c-Kit) …

Molecular targeted therapy for anticancer treatment.

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistanc

Совпадение в полном тексте источника
… , gefitinib, palbociclib, pazopanib, ponatinib, ruxolitinib, tofacitinib Type I 1/2 Type II | Binding in the ATP-binding pocket of the inactive conformation of the enzyme (type I 1/2 : DFG-Asp in; type II: DFG-Asp out) | dasatinib, imatinib, lapatinib, lenvatinib, nilotinib, regorafenib, sorafenib, sunitinib … Examples are sorafenib, sunitinib, pazopanib, lenvatinib, regorafenib, vandetanib, cabozantinib, axitinib, tivozanib, avapritinib, ripretinib, erdafitinib, pemigatinib, infigratinib, derazantinib, futibatinib, selpercatinib, and pralsetinib. …

A Review of the Regulatory Challenges of Personalized Medicine.

Personalized medicine integrates genomics with clinical and familial histories, revolutionizing healthcare by tailoring treatments to individual patient characteristics. At its core, pharmacogenomics enables the customization of medication prescriptions based on genetic profiles, enhancing drug efficacy and safety. This precision medicine approach addresses disease diagnosis, prevention, and treatment, offering targeted therapies for conditions like autoimmune disorders, rheumatoid arthritis, and neoplastic conditions. Examples of pharmacogenomics and personalized medicine include treatment fo

Совпадение в полном тексте источника
… Sunitinib (Sutent) targets multiple kinases, including those involved in tumor growth and angiogenesis, used for renal cell carcinoma (RCC) and gastrointestinal stromal tumors. … Despite these advances, some individuals may develop resistance to these medications, with sunitinib remaining a primary first-line treatment. To address resistance issues and enhance the efficacy of RCC therapy, combining drugs with complementary agents is recommended. …

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications.

The tumor microenvironment (TME) has been extensively investigated; however, it is complex and remains unclear, especially in elderly patients. Senescence is a cellular response to a variety of stress signals, which is characterized by stable arrest of the cell cycle and major changes in cell morphology and physiology. To the best of our knowledge, senescence leads to consistent arrest of tumor cells and remodeling of the tumor-immune microenvironment (TIME) by activating a set of pleiotropic cytokines, chemokines, growth factors, and proteinases, which constitute the senescence-associated sec

Совпадение в полном тексте источника
… | N = 1096; median age = 62 yr; 65 years: 38% | OS ≥ 75 yr, HR: 0.97 (0.48–1.95); OS 65–74 yr, HR: 0.86 (0.58–1.27); OS < 65 yr, HR: 0.53 (0.40–0.71) KEYNOTE-426 ( NCT02853331 ) [ 359 ] | 2019 | First line pembrolizumab + axitinib versus sunitinib | N = 861; median age = 62 yr; 65 years: 38% | OS ≥ … 65 yr, HR: 0.59 (0.36–0.97); OS < 65 yr, HR: 0.47 (0.30–0.73) JAVELIN 101 ( NCT02684006 ) [ 360 ] | 2019 | First line avelumab + axitinib versus sunitinib | N = 886; median age = 61 yr; 65 years: 38% | PFS ≥ 65 yr, HR: 0.70 (0.49–0.99); PFS < 65 yr, HR: 0.68 (0.54–0.87) Urothelial carcinoma KEYNOTE-045 …

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.

Glioblastoma (GBM), the most frequent and aggressive glial tumor, is currently treated as first line by the Stupp protocol, which combines, after surgery, radiotherapy and chemotherapy. For recurrent GBM, in absence of standard treatment or available clinical trials, various protocols including cytotoxic drugs and/or bevacizumab are currently applied. Despite these heavy treatments, the mean overall survival of patients is under 18 months. Many clinical studies are underway. Based on clinicaltrials.org and conducted up to 1 April 2020, this review lists, not only main, but all targeted therapi

Совпадение в полном тексте источника
… Sunitinib, an inhibitor of PDGFRα/β, c-kit, VEGFR1/2/3, FLT3 and RET, also provided disappointing results. A Phase II study did not show any clinical benefit of sunitinib in patients with recurrent GBMs compared to bevacizumab or conventional chemotherapies [ 166 ]. …

Targeting FGFR for cancer therapy.

The FGFR signaling pathway is integral to cellular activities, including proliferation, differentiation, and survival. Dysregulation of this pathway is implicated in numerous human cancers, positioning FGFR as a prominent therapeutic target. Here, we conduct a comprehensive review of the function, signaling pathways and abnormal alterations of FGFR, as well as its role in tumorigenesis and development. Additionally, we provide an in-depth analysis of pivotal phase 2 and 3 clinical trials evaluating the performance and safety of FGFR inhibitors in oncology, thereby shedding light on the current

Совпадение в полном тексте источника
… The findings indicated that anlotinib exhibited comparable efficacy to sunitinib, as evidenced by similar median PFS durations (17.5 months vs. 16.6 months), median OS durations (30.9 months vs. 30.5 months), and ORR (30.3% vs. 27.9%). … Furthermore, anlotinib demonstrated superior safety profiles when compared to sunitinib [ 178 ]. In the third-line or subsequent treatment of patients with small cell carcinoma, anlotinib showed better PFS and OS compared with placebo, while maintaining a favorable safety profile [ 179 ]. …

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.

Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, each of which has a distinct etiology, molecular profile, and clinicopathological features. While the majority of NECs originate in the pulmonary organs, extrapulmonary NECs occur most predominantly in the gastro-entero-pancreatic (GEP) system. Although platinum-based chemotherapy is the main therapeut

Совпадение в полном тексте источника
… Molecular-targeted agents such as everolimus (Eve) and sunitinib (Sun) are also available, with Sun currently approved for pancreatic NETs only. Peptide receptor radionuclide therapy (PRRT) is an option for patients with progressive NETs expressing SSTR after first-line therapy. … In addition, phase II trials in cases of GEP-NEN showed clinical activity of sunitinib, with a disease control rate (DCR) of 55% in 20 patients with GEP-NEC [ 206 ], and pazopanib with an ORR of 23% and median PFS of 5.8 months in 13 patients with GEP-NEC [ 207 ]. …